公开(公告)号：US20230343457A1

公开(公告)日：2023-10-26

申请号：US18340751

申请日：2023-06-23

Applicant: Dexcom, Inc.

Inventor： Martina Vettoretti ,  Andrea Facchinetti ,  Giovanni Sparacino ,  Claudio Cobelli

IPC: G16H50/50 ,  G16H20/17 ,  G16H50/20 ,  G16H40/60 ,  A61M5/172

CPC classification number: G16H50/20 ,  A61M5/1723 ,  G16H20/17 ,  G16H40/60 ,  G16H50/50 ,  A61M2205/50 ,  A61M2230/005 ,  A61M2230/201

Abstract: A mathematical model of type 1 diabetes (T1D) patient decision-making can be used to simulate, in silico, realistic glucose/insulin dynamics, for several days, in a variety of subjects who take therapeutic actions (e.g. insulin dosing) driven by either self-monitoring blood glucose (SMBG) or continuous glucose monitoring (CGM). The decision-making (DM) model can simulate real-life situations and everyday patient behaviors. Accurate submodels of SMBG and CGM measurement errors are incorporated in the comprehensive DM model. The DM model accounts for common errors the patients are used to doing in their diabetes management, such as miscalculations of meal carbohydrate content, early/delayed insulin administrations and missed insulin boluses. The DM model can be used to assess in silico if/when CGM can safely substitute SMBG in T1D management, to develop and test guidelines for CGM driven insulin dosing, to optimize and individualize off-line insulin therapies and to develop and test decision support systems.

公开(公告)号：US11183301B2

公开(公告)日：2021-11-23

申请号：US15158047

申请日：2016-05-18

Applicant: DexCom, Inc.

Inventor： Martina Vettoretti ,  Andrea Facchinetti ,  Giovanni Sparacino ,  Claudio Cobelli

IPC: G16H50/20 ,  G16H50/50 ,  G16H20/17 ,  G16H40/60 ,  A61M5/172

Abstract: A mathematical model of type 1 diabetes (T1D) patient decision-making can be used to simulate, in silico, realistic glucose/insulin dynamics, for several days, in a variety of subjects who take therapeutic actions (e.g. insulin dosing) driven by either self-monitoring blood glucose (SMBG) or continuous glucose monitoring (CGM). The decision-making (DM) model can simulate real-life situations and everyday patient behaviors, Accurate submodels of SMBG and CGM measurement errors are incorporated in the comprehensive DM model. The DM model accounts for common errors the patients are used to doing in their diabetes management, such as miscalculations of meal carbohydrate content, early/delayed insulin administrations and missed insulin boluses. The DM model can be used to assess in silico if/when CGM can safely substitute SMBG in T1D management, to develop and test guidelines for CGM driven insulin dosing, to optimize and individualize off-line insulin therapies and to develop and test decision support systems.

公开(公告)号：US11749408B2

公开(公告)日：2023-09-05

申请号：US17451609

申请日：2021-10-20

Applicant: DexCom, Inc.

Inventor： Martina Vettoretti ,  Andrea Facchinetti ,  Giovanni Sparacino ,  Claudio Cobelli

IPC: G08B21/04 ,  G16H50/20 ,  G16H50/50 ,  G16H20/17 ,  G16H40/60 ,  A61M5/172

CPC classification number: G16H50/20 ,  A61M5/1723 ,  G16H20/17 ,  G16H40/60 ,  G16H50/50 ,  A61M2205/50 ,  A61M2230/005 ,  A61M2230/201

Abstract: A mathematical model of type 1 diabetes (T1D) patient decision-making can be used to simulate, in silico, realistic glucose/insulin dynamics, for several days, in a variety of subjects who take therapeutic actions (e.g. insulin dosing) driven by either self-monitoring blood glucose (SMBG) or continuous glucose monitoring (CGM). The decision-making (DM) model can simulate real-life situations and everyday patient behaviors. Accurate submodels of SMBG and CGM measurement errors are incorporated in the comprehensive DM model. The DM model accounts for common errors the patients are used to doing in their diabetes management, such as miscalculations of meal carbohydrate content, early/delayed insulin administrations and missed insulin boluses. The DM model can be used to assess in silico if/when CGM can safely substitute SMBG in T1D management, to develop and test guidelines for CGM driven insulin dosing, to optimize and individualize off-line insulin therapies and to develop and test decision support systems.

公开(公告)号：US20200237271A1

公开(公告)日：2020-07-30

申请号：US16779503

申请日：2020-01-31

Applicant: DexCom, Inc.

Inventor： Stephen J. Vanslyke ,  Giada Acciaroli ,  Martina Vettoretti ,  Andrea Facchinetti ,  Giovanni Sparacino

IPC: A61B5/145 ,  A61B5/00

Abstract: A method for monitoring a blood glucose level of a user is provided. The method includes receiving a time-varying electrical signal from an analyte sensor during a temporal phase of a monitoring session. The method includes selecting a calibration model from a plurality of calibration models, wherein the selected calibration model comprises one or more calibration model parameters. The method includes estimating at least one of the one or more calibration model parameters of the selected calibration model based on at least the time-varying electrical signal during the temporal phase of the monitoring session. The method includes estimating the blood glucose level of the user based on the selected calibration model and using the at least one estimated parameter. An apparatus and non-transitory computer readable medium having similar functionality are also provided.